{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    50,
    51,
    52,
    53,
    68
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_llm_1",
        "definition": "Initiation of ALXN1840 treatment",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 60,
        "sourceText": "The accumulation period refers to time from initiation of ALXN1840 (Day 1) to expected steady state at Day 10",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_1",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 50,
        "sourceText": "Baseline Day",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "informed consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 9,
        "intraDayOrder": 100,
        "sourceText": "procedure",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_collection_1",
        "definition": "24-hour collection period",
        "anchorType": "CollectionDay",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 90,
        "sourceText": "24-hour urine",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "daily urine"
      },
      {
        "id": "rep_daily_2",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_4",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_67",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "interval": "PT8H",
        "sourceText": "every \n8 hours"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P4D",
        "endOffset": "-P1D",
        "sourceText": "Days -4 through -1"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "-P7D",
        "endOffset": "-P5D",
        "sourceText": "Day -7 through Day -5"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "startOffset": "-P4D",
        "endOffset": "-P1D",
        "sourceText": "Day -4 through Day -1"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P8D",
        "sourceText": "Day 1 through Day 8"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "startOffset": "P25D",
        "endOffset": "P39D",
        "sourceText": "Day 25 through Day 39"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P28D",
        "sourceText": "Day 1 through Day 28"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "startOffset": "P29D",
        "endOffset": "P39D",
        "sourceText": "Day 29 through Day 39"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "startOffset": "P25D",
        "endOffset": "P28D",
        "sourceText": "Days 25 through 28"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "startOffset": "P29D",
        "endOffset": "P39D",
        "sourceText": "Days 29 through 39"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "startOffset": "P4D",
        "endOffset": "P7D",
        "sourceText": "Days 4 - 7"
      },
      {
        "id": "rep_window_15",
        "type": "Continuous",
        "startOffset": "P26D",
        "endOffset": "P28D",
        "sourceText": "Days 26 - 28"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "startOffset": "P30D",
        "endOffset": "P38D",
        "sourceText": "Days 30 - 38"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "startOffset": "-P8D",
        "endOffset": "P9D",
        "sourceText": "Day -8 to Day 9"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "startOffset": "P23D",
        "endOffset": "P40D",
        "sourceText": "Day 23 to Day 40"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "startOffset": "P25D",
        "endOffset": "P28D",
        "sourceText": "Day 25 through Day 28"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "startOffset": "P36D",
        "endOffset": "P39D",
        "sourceText": "Day 36 through Day 39"
      },
      {
        "id": "rep_window_22",
        "type": "Continuous",
        "startOffset": "-P7D",
        "endOffset": "-P5D",
        "sourceText": "Day -7 through \nDay -5"
      },
      {
        "id": "rep_window_29",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P9D",
        "sourceText": "Days 1 through 9"
      },
      {
        "id": "rep_window_30",
        "type": "Continuous",
        "startOffset": "P31D",
        "endOffset": "P35D",
        "sourceText": "Days 31 through 35"
      },
      {
        "id": "rep_window_32",
        "type": "Continuous",
        "startOffset": "P36D",
        "endOffset": "P39D",
        "sourceText": "Days 36 through 39"
      },
      {
        "id": "rep_window_33",
        "type": "Continuous",
        "startOffset": "P9D",
        "endOffset": "P23D",
        "sourceText": "Day 9 to Day 23"
      },
      {
        "id": "rep_window_34",
        "type": "Continuous",
        "sourceText": "Run-in Period"
      },
      {
        "id": "rep_window_39",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_40",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_46",
        "type": "Continuous",
        "sourceText": "treatment \nperiod"
      },
      {
        "id": "rep_window_51",
        "type": "Continuous",
        "sourceText": "dosing period"
      },
      {
        "id": "rep_window_52",
        "type": "Continuous",
        "sourceText": "pretreatment period"
      },
      {
        "id": "rep_window_53",
        "type": "Continuous",
        "sourceText": "post-treatment period"
      },
      {
        "id": "rep_window_54",
        "type": "Continuous",
        "sourceText": "2 hours after"
      },
      {
        "id": "rep_window_56",
        "type": "Continuous",
        "sourceText": "8 hours before"
      },
      {
        "id": "rep_window_57",
        "type": "Continuous",
        "sourceText": "4 hours post"
      },
      {
        "id": "rep_window_58",
        "type": "Continuous",
        "sourceText": "21 days after"
      },
      {
        "id": "rep_window_59",
        "type": "Continuous",
        "sourceText": "Inpatient Period"
      },
      {
        "id": "rep_window_60",
        "type": "Continuous",
        "sourceText": "inpatient Period"
      },
      {
        "id": "rep_window_62",
        "type": "Continuous",
        "sourceText": "Inpatient \nPeriod"
      },
      {
        "id": "rep_window_64",
        "type": "Continuous",
        "sourceText": "inpatient period"
      },
      {
        "id": "rep_window_67",
        "type": "Continuous",
        "sourceText": "inpatient \nperiod"
      },
      {
        "id": "rep_window_70",
        "type": "Continuous",
        "sourceText": "balance period"
      },
      {
        "id": "rep_window_71",
        "type": "Continuous",
        "sourceText": "24-hour urine"
      },
      {
        "id": "rep_window_72",
        "type": "Continuous",
        "sourceText": "24-hour collection"
      },
      {
        "id": "rep_daily_bound_1",
        "type": "Daily",
        "startOffset": "-P8D",
        "endOffset": "P9D",
        "interval": "P1D",
        "count": 18,
        "sourceText": "controlled diet (Day -8 to Day 9)"
      },
      {
        "id": "rep_daily_bound_3",
        "type": "Daily",
        "startOffset": "P23D",
        "endOffset": "P40D",
        "interval": "P1D",
        "count": 18,
        "sourceText": "controlled diet (Day 23 to Day 40)"
      },
      {
        "id": "rep_daily_bound_5",
        "type": "Daily",
        "startOffset": "-P7D",
        "endOffset": "-P5D",
        "interval": "P1D",
        "count": 3,
        "sourceText": "controlled diet (Day -7 through \nDay -5)"
      },
      {
        "id": "rep_daily_bound_6",
        "type": "Daily",
        "startOffset": "-P4D",
        "endOffset": "-P1D",
        "interval": "P1D",
        "count": 4,
        "sourceText": "controlled diet (Day -4 through Day -1)"
      },
      {
        "id": "rep_daily_bound_11",
        "type": "Daily",
        "startOffset": "P3D",
        "endOffset": "P15D",
        "interval": "P1D",
        "count": 13,
        "sourceText": "controlled diet (3 to 15)"
      },
      {
        "id": "rep_daily_bound_12",
        "type": "Daily",
        "startOffset": "P101D",
        "endOffset": "P201D",
        "interval": "P1D",
        "count": 101,
        "sourceText": "copper balance (101-201)"
      },
      {
        "id": "rep_daily_bound_13",
        "type": "Daily",
        "startOffset": "-P4D",
        "endOffset": "-P1D",
        "interval": "P1D",
        "count": 4,
        "sourceText": "copper balance (Days -4 through -1)"
      },
      {
        "id": "rep_daily_bound_14",
        "type": "Daily",
        "startOffset": "-P7D",
        "endOffset": "-P5D",
        "interval": "P1D",
        "count": 3,
        "sourceText": "molybdenum balance (Day -7 through Day -5)"
      },
      {
        "id": "rep_daily_bound_15",
        "type": "Daily",
        "startOffset": "-P4D",
        "endOffset": "-P1D",
        "interval": "P1D",
        "count": 4,
        "sourceText": "molybdenum balance (Day -4 through Day -1)"
      },
      {
        "id": "rep_daily_bound_17",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P8D",
        "interval": "P1D",
        "count": 8,
        "sourceText": "molybdenum balance (Day 1 through Day 8)"
      },
      {
        "id": "rep_daily_bound_18",
        "type": "Daily",
        "startOffset": "P25D",
        "endOffset": "P39D",
        "interval": "P1D",
        "count": 15,
        "sourceText": "molybdenum balance (Day 25 through Day 39)"
      },
      {
        "id": "rep_daily_bound_22",
        "type": "Daily",
        "startOffset": "-P7D",
        "endOffset": "-P5D",
        "interval": "P1D",
        "count": 3,
        "sourceText": "molybdenum balance (Day -7 through \nDay -5)"
      },
      {
        "id": "rep_daily_bound_24",
        "type": "Daily",
        "startOffset": "-P8D",
        "endOffset": "P9D",
        "interval": "P1D",
        "count": 18,
        "sourceText": "molybdenum balance (Day -8 to Day 9)"
      },
      {
        "id": "rep_daily_bound_25",
        "type": "Daily",
        "startOffset": "P23D",
        "endOffset": "P40D",
        "interval": "P1D",
        "count": 18,
        "sourceText": "molybdenum balance (Day 23 to Day 40)"
      },
      {
        "id": "rep_daily_bound_29",
        "type": "Daily",
        "startOffset": "P3D",
        "endOffset": "P15D",
        "interval": "P1D",
        "count": 13,
        "sourceText": "copper balance (3 to 15)"
      },
      {
        "id": "rep_daily_bound_30",
        "type": "Daily",
        "startOffset": "P3D",
        "endOffset": "P15D",
        "interval": "P1D",
        "count": 13,
        "sourceText": "molybdenum balance (3 to 15)"
      },
      {
        "id": "rep_daily_bound_31",
        "type": "Daily",
        "startOffset": "P101D",
        "endOffset": "P301D",
        "interval": "P1D",
        "count": 201,
        "sourceText": "molybdenum balance (101-301)"
      },
      {
        "id": "rep_daily_bound_32",
        "type": "Daily",
        "startOffset": "P3D",
        "endOffset": "P5D",
        "interval": "P1D",
        "count": 3,
        "sourceText": "copper \nbalance (3 - 5)"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_2",
          "epoch_3",
          "epoch_4",
          "epoch_5",
          "epoch_6",
          "epoch_7"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "End of Study",
          "Screening"
        ],
        "sourceText": "[{'condition': 'US-based participants at specific screening sites', 'path': ['SCREENING_SITE_PROCEDURES', 'TRANSFER_TO_MAIN_SITE']}, {'condition': 'Participant experiences AE or withdrawal criteria', 'path': ['DISCONTINUATION', 'EARLY_TERMINATION_VISIT', 'FOLLOW_UP']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Urine Collection",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Window",
        "rationale": "WINDOW signals: 5; EPISODE signals: 2; SINGLE signals: 1; RECURRING signals: 1"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Window",
        "rationale": "WINDOW signals: 7"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant Medication",
        "executionType": "Single",
        "rationale": "WINDOW signals: 1; SINGLE signals: 4; RECURRING signals: 2"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Window",
        "rationale": "WINDOW signals: 3; EPISODE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Screening Procedures",
        "executionType": "Single",
        "rationale": "The protocol specifies screening procedures occur at a single phase (Screening) to determine eligibility."
      },
      {
        "activityId": "Zinc Discontinuation",
        "executionType": "Single",
        "rationale": "The protocol describes a 21-day period following the discontinuation of zinc to allow for gastrointestinal cell turnover."
      },
      {
        "activityId": "Copper and Molybdenum Balance Assessment",
        "executionType": "Single",
        "rationale": "The study title and summary indicate assessments are performed on participants treated with ALXN1840, implying scheduled repeats during the treatment period."
      },
      {
        "activityId": "US-Specific Screening Site Procedures",
        "executionType": "Single",
        "rationale": "Section 8 specifies that certain US sites may only perform screening procedures and no other study activities."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. Within 42 days of ALXN1840 administration. Details of procedures that may be performed by sites designated as “screening sites” (only in the US) are detailed in Section 8.",
        "footnoteId": "fn_1",
        "structuredCondition": "timing.within(screening_procedures, ALXN1840_administration, P42D)",
        "appliesToActivityIds": [
          "Screening Procedures"
        ],
        "sourceText": "a. Within 42 days of ALXN1840 administration. Details of procedures that may be performed by sites d"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "b. Participants will be admitted to the clinical research unit (CRU) at least 10 hours prior to enrollment and initiation of copper- and molybdenum-controlled diet.",
        "footnoteId": "fn_2",
        "structuredCondition": "timing.before(enrollment and initiation of copper- and molybdenum-controlled diet., PT10M)",
        "appliesToActivityIds": [
          "CRU Admission"
        ],
        "timingConstraint": "PT10H",
        "sourceText": "b. Participants will be admitted to the clinical research unit (CRU) at least 10 hours prior to enro"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_at",
        "text": "c. At the CRU’s discretion, participants may remain in the CRU or be readmitted on Day 22 with all procedures starting on Day 23.",
        "footnoteId": "fn_3",
        "structuredCondition": "if(CRU_discretion) { stay_in_CRU } else { readmit(Day22) }",
        "appliesToActivityIds": [
          "CRU Stay",
          "Readmission"
        ],
        "sourceText": "c. At the CRU’s discretion, participants may remain in the CRU or be readmitted on Day 22 with all p"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d. Unscheduled study visits may occur at any time during the study and may include any study procedure as deemed necessary by the Investigator.",
        "footnoteId": "fn_4",
        "structuredCondition": "frequency.as_needed(investigator_discretion)",
        "appliesToActivityIds": [
          "Unscheduled study visits"
        ],
        "sourceText": "d. Unscheduled study visits may occur at any time during the study and may include any study procedu"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "e. Participants are required to return to the CRU Day 54+/-2; participants will be discontinued from ALXN1840 medication by their physician at the latest by the Day 54 follow-up.",
        "footnoteId": "fn_5",
        "structuredCondition": "timing.at(Day54, +/-P2D)",
        "appliesToActivityIds": [
          "CRU Return",
          "Discontinuation of ALXN1840"
        ],
        "sourceText": "e. Participants are required to return to the CRU Day 54+/-2; participants will be discontinued from"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_after",
        "text": "f. Discharge from the unit may occur after completion of all procedures on Day 9 and on Day 40 and after the Investigator has reviewed all safety assessment (including safety laboratory tests) and confirmed that the participant is appropriate for discharge.",
        "footnoteId": "fn_6",
        "structuredCondition": "sequence.after(discharge, [all_procedures, safety_assessment_review])",
        "appliesToActivityIds": [
          "Discharge"
        ],
        "sourceText": "f. Discharge from the unit may occur after completion of all procedures on Day 9 and on Day 40 and a"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "g. A single outpatient visit or phone call and safety laboratory assessment should occur between Day 14 and Day 18. A phone call may take place on a different day than the blood draw within the Day 14 through Day 18 period.",
        "footnoteId": "fn_7",
        "structuredCondition": "timing.between(Day14, Day18)",
        "appliesToActivityIds": [
          "Outpatient visit",
          "Phone call",
          "Safety laboratory assessment"
        ],
        "sourceText": "g. A single outpatient visit or phone call and safety laboratory assessment should occur between Day"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "h. If needed to confirm menopause.",
        "footnoteId": "fn_8",
        "structuredCondition": "if(needed_to_confirm_menopause)",
        "appliesToActivityIds": [
          "FSH/Menopause testing"
        ],
        "sourceText": "h. If needed to confirm menopause."
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "i. Parameters include age and sex. Race and ethnicity will be collected where permitted by local regulations.",
        "footnoteId": "fn_9",
        "sourceText": "i. Parameters include age and sex. Race and ethnicity will be collected where permitted by local reg"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "j. Wilson disease history will include diagnosis date, method of diagnosis, history of cirrhosis, details of any previous liver biopsies performed, and treatment received.",
        "footnoteId": "fn_10",
        "sourceText": "j. Wilson disease history will include diagnosis date, method of diagnosis, history of cirrhosis, de"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "timing_before",
        "text": "k. A full physical examination will be performed at Screening, at check-in for the study, and at the End of the study/Early Termination Visit. A physical examination should also be performed on any participants with ongoing adverse events prior to discharge from the unit. Otherwise, a symptom-driven physical examination may be performed at other times, at the Principal Investigator’s discretion.",
        "footnoteId": "fn_11",
        "structuredCondition": "if(ongoing_AE) { full_physical_exam } else { symptom_driven_physical_exam }",
        "appliesToActivityIds": [
          "Physical examination"
        ],
        "sourceText": "k. A full physical examination will be performed at Screening, at check-in for the study, and at the"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "l. Height at screening only.",
        "footnoteId": "fn_12",
        "sourceText": "l. Height at screening only."
      },
      {
        "id": "fn_cond_13",
        "conditionType": "timing_after",
        "text": "m. While in the CRU, study intervention will be administered after an overnight fast (ie, at least 10 hours) at the same time every morning; drug is to be administered with 240 mL of water and meals should be delayed a minimum of 2 hours after dosing. As an outpatient, participants are expected to take ALXN1840 at approximately the same time daily (+/-1 hour). Participants should take the medication with a glass of water on an empty stomach; meals should be delayed a minimum of 2 hours after dosing.",
        "footnoteId": "fn_13",
        "structuredCondition": "timing.after(dosing. as an outpatient, participants are expected to take alxn1840 at approximately the same time daily (+/-1 hour). participants should take the medication with a glass of water on an empty stomach; meals should be delayed a minimum of 2 hours after dosing., PT2M)",
        "appliesToActivityIds": [
          "ALXN1840 administration"
        ],
        "timingConstraint": "PT10H",
        "sourceText": "m. While in the CRU, study intervention will be administered after an overnight fast (ie, at least 1"
      },
      {
        "id": "fn_cond_14",
        "conditionType": "general",
        "text": "n. During the outpatient period, participants will use SMS text messaging to confirm study intervention administration.",
        "footnoteId": "fn_14",
        "sourceText": "n. During the outpatient period, participants will use SMS text messaging to confirm study intervent"
      },
      {
        "id": "fn_cond_15",
        "conditionType": "timing_before",
        "text": "o. Blood sampling for PK/PD will occur before ALXN1840 administration and represents a predose trough. See Table 2 for PK/PD sampling on Days 1, 25, 29, and 39.",
        "footnoteId": "fn_15",
        "structuredCondition": "timing.before(PK_PD_sampling, ALXN1840_administration)",
        "appliesToActivityIds": [
          "Blood sampling for PK/PD"
        ],
        "sourceText": "o. Blood sampling for PK/PD will occur before ALXN1840 administration and represents a predose troug"
      },
      {
        "id": "fn_cond_16",
        "conditionType": "general",
        "text": "p. PK/PD collection will include timepoints described in the schedule of PK/PD assessment for Days 1, 25, 29, and 39 (Table 2).",
        "footnoteId": "fn_16",
        "sourceText": "p. PK/PD collection will include timepoints described in the schedule of PK/PD assessment for Days 1"
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_before",
        "text": "q. Samples for serum chemistry will be obtained following a fast of at least 8 hours at the Screening Visit and at check-in. In case of rechecks, and postdose serum chemistry, participants may not have fasted for 6 or 8 hours before the serum chemistry sample is taken.",
        "footnoteId": "fn_17",
        "structuredCondition": "timing.before(the serum chemistry sample is taken., PT8M)",
        "appliesToActivityIds": [
          "Serum chemistry"
        ],
        "timingConstraint": "PT8H",
        "sourceText": "q. Samples for serum chemistry will be obtained following a fast of at least 8 hours at the Screenin"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "general",
        "text": "r. Laboratory assessment including chemistry, hematology, and coagulation parameters should be performed on Days -8, -1, 8, 23, and 28 only.",
        "footnoteId": "fn_18",
        "sourceText": "r. Laboratory assessment including chemistry, hematology, and coagulation parameters should be perfo"
      },
      {
        "id": "fn_cond_19",
        "conditionType": "timing_after",
        "text": "s. Menstruation check is for women only; women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening. Additional urine pregnancy testing will be standard for the protocol unless serum testing is required by site policies, local regulation, or Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) (Section 10.2). In addition to pregnancy tests detailed at the visits in the SoA, females of childbearing potential will be required to perform urine pregnancy tests at least every 4 weeks at their home or the study site throughout their time in the study.",
        "footnoteId": "fn_19",
        "structuredCondition": "if(female_of_childbearing_potential) { pregnancy_test.frequency(P4W) }",
        "appliesToActivityIds": [
          "Urine pregnancy testing"
        ],
        "sourceText": "s. Menstruation check is for women only; women of childbearing potential should only be enrolled aft"
      },
      {
        "id": "fn_cond_20",
        "conditionType": "timing_after",
        "text": "t. A single 15 mL serum sample will be retained for evaluation in the event of an unexpected safety finding; retained samples may be destroyed after completion of the clinical report.",
        "footnoteId": "fn_20",
        "sourceText": "t. A single 15 mL serum sample will be retained for evaluation in the event of an unexpected safety "
      },
      {
        "id": "fn_cond_21",
        "conditionType": "general",
        "text": "u. Vital signs measurements and ECGs should be performed predose, unless otherwise specified. Vitals signs include body temperature, heart rate, respiratory rate, and systolic and diastolic blood pressure.",
        "footnoteId": "fn_21",
        "structuredCondition": "timing.before(vital_signs, dose) && timing.before(ECG, dose)",
        "appliesToActivityIds": [
          "Vital signs",
          "ECG"
        ],
        "sourceText": "u. Vital signs measurements and ECGs should be performed predose, unless otherwise specified. Vitals"
      },
      {
        "id": "fn_cond_22",
        "conditionType": "timing_after",
        "text": "v. Copper- and molybdenum-controlled diet will be initiated after registration/inclusion. Participants will remain on a copper/molybdenum controlled diet throughout both the inpatient Period 1 (Day -8 to Day 9) and inpatient Period 2 (Day 23 to Day 40); during this time participants will be strongly encouraged to complete all meals. While not in the CRU, participants will be encouraged to adhere to their usual copper-controlled diet.",
        "footnoteId": "fn_22",
        "sourceText": "v. Copper- and molybdenum-controlled diet will be initiated after registration/inclusion. Participan"
      },
      {
        "id": "fn_cond_23",
        "conditionType": "general",
        "text": "w. For each input/output balance period, 24-hour urine samples are to be collected for measurement of copper and molybdenum.",
        "footnoteId": "fn_23",
        "sourceText": "w. For each input/output balance period, 24-hour urine samples are to be collected for measurement o"
      },
      {
        "id": "fn_cond_24",
        "conditionType": "general",
        "text": "x. For fecal samples, each individual sample will be independently collected with record of date, time, and weight of the sample.",
        "footnoteId": "fn_24",
        "sourceText": "x. For fecal samples, each individual sample will be independently collected with record of date, ti"
      },
      {
        "id": "fn_cond_25",
        "conditionType": "frequency_continuous",
        "text": "1. Participants eligible for the study will be enrolled on Day -7 and initiated on a copper- and molybdenum- controlled diet, which will be continued during Treatment Period 1 and Treatment Period 2 when in the CRU, through Day 39.",
        "footnoteId": "fn_25",
        "sourceText": "1. Participants eligible for the study will be enrolled on Day -7 and initiated on a copper- and mol"
      },
      {
        "id": "fn_cond_26",
        "conditionType": "timing_at",
        "text": "2. Participants will be admitted to the CRU for Treatment Period 1 on Day -8 and may be discharged on Day 9 or remain in the CRU for their own safety or to maintain the integrity of the conduct of the study. Participants who are discharged will be re-admitted on Day 22 or Day 23 for Treatment Period 2 and will remain in house until Day 40. To ensure flexibility, the Outpatient Period may be extended up to an additional 14 days with Investigator approval. In this situation, participants will be given additional investigational product to support daily dosing throughout the Outpatient Period. In such cases, the actual Outpatient Period duration will be recorded and the participant will continue Inpatient Period 2 at Day 23.",
        "footnoteId": "fn_26",
        "structuredCondition": "timing.extend(outpatient_period, P14D)",
        "appliesToActivityIds": [
          "Outpatient Period"
        ],
        "sourceText": "2. Participants will be admitted to the CRU for Treatment Period 1 on Day -8 and may be discharged o"
      },
      {
        "id": "fn_cond_27",
        "conditionType": "timing_at",
        "text": "3. Participants will be administered ALXN1840 at a dose of 15 mg/day on Day 1 through Day 28 and then increase to 30 mg/day on Day 29 through Day 39. During the Outpatient Period, participants will use SMS text messaging to confirm study intervention administration.",
        "footnoteId": "fn_27",
        "sourceText": "3. Participants will be administered ALXN1840 at a dose of 15 mg/day on Day 1 through Day 28 and the"
      },
      {
        "id": "fn_cond_28",
        "conditionType": "general",
        "text": "4. Participants will have 3 intake and output collection periods including: • Baseline Day -4 through Day -1 • Day 1 through Day 8 (I/O for 15 mg) • Day 25 through Day 39 (Days 25 through 28, I/O for 15 mg; Days 29 through 39, I/O for 30 mg)",
        "footnoteId": "fn_28",
        "sourceText": "4. Participants will have 3 intake and output collection periods including: • Baseline Day -4 throug"
      },
      {
        "id": "fn_cond_29",
        "conditionType": "general",
        "text": "5. During these periods all intake (including food and drink) and output (including urine and feces) will be collected and assessed for copper and molybdenum.",
        "footnoteId": "fn_29",
        "sourceText": "5. During these periods all intake (including food and drink) and output (including urine and feces)"
      },
      {
        "id": "fn_cond_30",
        "conditionType": "general",
        "text": "6. Blood sampling for PK/PD will be as follows: • PK/PD collection (24-hour): Days 1, 25, 29, and 39 • Predose PK/PD sampling days: Days 4 - 7, Days 26 - 28, Days 30 - 38 • End of Study Visit Day 54 +/- 2 days Abbreviations: AP = accumulation period; CRU = clinical research unit; EOS = End of Study; I/O = input/output; PD = pharmacodynamic; PK = pharmacokinetic; SS = steady state.",
        "footnoteId": "fn_30",
        "sourceText": "6. Blood sampling for PK/PD will be as follows: • PK/PD collection (24-hour): Days 1, 25, 29, and 39"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Net Negative Copper Balance",
        "endpointType": "Primary",
        "inputs": [
          "Copper intake (food and drink)",
          "Copper output (feces)",
          "Copper output (urine)"
        ],
        "timeWindow": {
          "reference": "Baseline to post-Baseline",
          "duration": "Daily repeat-dose period"
        },
        "algorithm": "Copper Balance = (Copper intake) - (Copper output in feces + Copper output in urine)",
        "successCriteria": "Copper Balance < 0 (Net negative balance)",
        "sourceText": "The primary objective of this study is to demonstrate a net negative copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with WD."
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Mean daily copper balance",
        "variableType": "Custom",
        "sourceVariables": [
          "copper intake in food",
          "copper intake in drink",
          "copper output in feces",
          "copper output in urine"
        ],
        "derivationRule": "(copper intake in food + copper intake in drink) - (copper output in feces + copper output in urine)",
        "baselineDefinition": "Days -4 through -1",
        "baselineVisit": "Pretreatment",
        "analysisWindow": "Accumulation and steady-state periods for each dose",
        "imputationRule": "Not specified",
        "unit": "mg/day"
      },
      {
        "id": "dv_2",
        "name": "Change in mean daily copper balance",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "copper intake in food",
          "copper intake in drink",
          "copper output in feces",
          "copper output in urine"
        ],
        "derivationRule": "mean_daily_copper_balance_at_period - mean_daily_copper_balance_at_baseline",
        "baselineDefinition": "Mean daily copper balance measured during Days -4 through -1",
        "baselineVisit": "Days -4 through -1",
        "analysisWindow": "Accumulation and steady-state periods for each dose",
        "imputationRule": "Not specified",
        "unit": "mg/day"
      },
      {
        "id": "dv_3",
        "name": "Mean daily molybdenum balance",
        "variableType": "Custom",
        "sourceVariables": [
          "molybdenum intake in food",
          "molybdenum intake in drink",
          "molybdenum intake in ALXN1840",
          "molybdenum output in feces",
          "molybdenum output in urine"
        ],
        "derivationRule": "(molybdenum intake in food + drink + ALXN1840) - (molybdenum output in feces + urine)",
        "baselineDefinition": "Not specified",
        "baselineVisit": "Not specified",
        "analysisWindow": "ALXN1840 steady state",
        "imputationRule": "Not specified",
        "unit": "mg/day"
      },
      {
        "id": "dv_4",
        "name": "NCCcorrected",
        "variableType": "Custom",
        "sourceVariables": [
          "plasma non-ceruloplasmin-bound copper (NCC)",
          "tetrathiomolybdate-copper-albumin tripartite complex (TPC)"
        ],
        "derivationRule": "NCC corrected for the stable TPC",
        "baselineDefinition": "Not specified",
        "baselineVisit": "Not specified",
        "analysisWindow": "Not specified",
        "imputationRule": "Not specified",
        "unit": "Not specified"
      },
      {
        "id": "dv_5",
        "name": "Change in ceruloplasmin",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "ceruloplasmin"
        ],
        "derivationRule": "post_dose_value - predose_value",
        "baselineDefinition": "Predose value",
        "baselineVisit": "Day 1 (Predose)",
        "analysisWindow": "Days 1, 8, 25, 29, 36, and Day 39",
        "imputationRule": "Not specified",
        "unit": "Not specified"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "C-I",
        "Inpatient Period 1",
        "OP",
        "Inpatient Period 2",
        "UNS",
        "EOS or ET",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "C-I",
          "trigger": "Progress to C-I"
        },
        {
          "fromState": "C-I",
          "toState": "Inpatient Period 1",
          "trigger": "Progress to Inpatient Period 1"
        },
        {
          "fromState": "Inpatient Period 1",
          "toState": "OP",
          "trigger": "Progress to OP"
        },
        {
          "fromState": "OP",
          "toState": "Inpatient Period 2",
          "trigger": "Progress to Inpatient Period 2"
        },
        {
          "fromState": "Inpatient Period 2",
          "toState": "UNS",
          "trigger": "Progress to UNS"
        },
        {
          "fromState": "UNS",
          "toState": "EOS or ET",
          "trigger": "Progress to EOS or ET"
        },
        {
          "fromState": "Inpatient Period 1",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Inpatient Period 2",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "epoch_1",
        "C_I": "epoch_2",
        "Inpatient_Period_1": "epoch_3",
        "OP": "epoch_4",
        "Inpatient_Period_2": "epoch_5",
        "UNS": "epoch_6",
        "EOS_or_ET": "epoch_7",
        "Early_Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "ALXN1840",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 30.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "Not specified in provided text",
        "doseModifications": [
          "Dose Modification details are located in Section 6.6 (page 38) according to the Table of Contents."
        ],
        "sourceText": "Administration of Study Interventionm ALXN1840 15 mg/day           ALXN1840 30 mg/day      Study intervention compliance Xn  PK/PD Analyseso"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Zinc",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Discontinued 21 days prior to study procedures as per Section 4.2 amendment."
      }
    ],
    "visitWindows": [
      {
        "id": "visit_4",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "treatment-naïve participants are eligible for this study. Following screening and enrollment, participants will have a Run-in Period to support diet equilibration (Day -7 through Day -5) and measureme"
      },
      {
        "id": "visit_llm_2",
        "visitName": "Enrollment / Diet Equilibration",
        "targetDay": -7,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "epoch": "Run-in Period"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Pretreatment Baseline Collection",
        "targetDay": -4,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Run-in Period"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Assess net copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with Wilson disease (WD)"
      },
      {
        "id": "visit_2",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "periods versus the pretreatment baseline in participants with WD Change in mean daily copper balance as measured by the"
      },
      {
        "id": "visit_13",
        "visitName": "End of Study",
        "targetDay": null,
        "windowBefore": 2,
        "windowAfter": 2,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "End of Study Visit Day 54 +/- 2 days Abbreviations: AP = accumulation period; CRU = clinical research unit; EOS = End of Study; I/O = input/output; PD = pharmacodynamic; PK = pharmacokinetic; SS = ste"
      },
      {
        "id": "visit_3",
        "visitName": "Day 1",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Treatment Period 1",
        "sourceText": "Note: The accumulation period refers to time from initiation of ALXN1840 (Day 1) to expected steady state at Day 10, based on 5 times the half-life of 2 days. Overall Design"
      },
      {
        "id": "visit_17",
        "visitName": "Day 7",
        "targetDay": 7,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "Day 7, indicating the possibility of tissue accumulation, particularly in the setting of high liver copper concentration (Plitz, 2019). If the half-life of ALXN1840 in liver were longer than that of t"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Day 8",
        "targetDay": 8,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 2,
        "epoch": "Treatment Period 1"
      },
      {
        "id": "visit_7",
        "visitName": "Day 9",
        "targetDay": 9,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "epoch": "Treatment Period 1 (Outpatient)",
        "sourceText": "Participants may be discharged from the clinical research unit (CRU) on Day 9 to return on Day 22 or Day 23 (predose); all procedures will start on Day 23. To ensure flexibility, the Outpatient Period"
      },
      {
        "id": "visit_15",
        "visitName": "Day 14",
        "targetDay": 14,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 11,
        "sourceText": "g A single outpatient visit or phone call and safety laboratory assessment should occur between Day 14 and Day 18. A phone call may take place on a different day than the blood draw within the Day 14 "
      },
      {
        "id": "visit_9",
        "visitName": "Day 22",
        "targetDay": 22,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "who are discharged will be re-admitted on Day 22 or Day 23 for Treatment Period 2 and will remain in house until Day 40. To ensure flexibility, the Outpatient Period may be extended up to an additiona"
      },
      {
        "id": "visit_6",
        "visitName": "Day 23",
        "targetDay": 23,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "epoch": "Treatment Period 1 (Inpatient 2)",
        "sourceText": "data through Day 23 for each participant. Participants will have intake and output collection periods from Day -4 through Day -1, from Day 1 through Day 8 (initial 15 mg/day collection period), and Da"
      },
      {
        "id": "visit_11",
        "visitName": "Day 25",
        "targetDay": 25,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "epoch": "Treatment Period 1",
        "sourceText": "Day 25 through Day 39 (Days 25 through 28, I/O for 15 mg; Days 29 through 39, I/O for 30 mg) 5. During these periods all intake (including food and drink) and output (including urine and feces) will b"
      },
      {
        "id": "visit_5",
        "visitName": "Day 29",
        "targetDay": 29,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 15,
        "epoch": "Treatment Period 2",
        "sourceText": "treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29. Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Da"
      },
      {
        "id": "visit_16",
        "visitName": "Day 36",
        "targetDay": 36,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "epoch": "Treatment Period 2",
        "sourceText": "Day 36 through Day 39 for the 30 mg/day dose: if steady state is achieved, molybdenum(out) will equal molybdenum(in). 2.2."
      },
      {
        "id": "visit_8",
        "visitName": "Day 39",
        "targetDay": 39,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 17,
        "epoch": "Treatment Period 2",
        "sourceText": "through Day 39. 2. Participants will be admitted to the CRU for Treatment Period 1 on Day -8 and may be discharged on Day 9 or remain in the CRU for their own safety or to maintain the integrity of th"
      },
      {
        "id": "visit_10",
        "visitName": "Day 40",
        "targetDay": 40,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 18,
        "sourceText": "until Day 40. To ensure flexibility, the Outpatient Period may be extended up to an additional 14 days with Investigator approval. In this situation, participants will be given additional investigatio"
      },
      {
        "id": "visit_12",
        "visitName": "Day 54",
        "targetDay": 54,
        "windowBefore": 2,
        "windowAfter": 2,
        "isRequired": true,
        "visitNumber": 19,
        "sourceText": "End of Study Visit Day 54 +/- 2 days Abbreviations: AP = accumulation period; CRU = clinical research unit; EOS = End of Study; I/O = input/output; PD = pharmacodynamic; PK = pharmacokinetic; SS = ste"
      },
      {
        "id": "visit_18",
        "visitName": "Week 24",
        "targetDay": 162,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 20,
        "targetWeek": 24,
        "sourceText": "for 9 participants at Week 24 when the primary endpoint assessment was conducted, or at the last dose received for participants with early discontinuation. The 15 to 60 mg/day dose range has been demo"
      },
      {
        "id": "visit_14",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 21,
        "sourceText": "Day 54 follow-up. f Discharge from the unit may occur after completion of all procedures on Day 9 and on Day 40 and after the Investigator has reviewed all safety assessment (including safety laborato"
      }
    ],
    "activityBindings": [
      {
        "id": "binding_1",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_1",
        "expectedOccurrences": 18,
        "sourceText": "Daily controlled_meal from Day -8 to Day 9"
      },
      {
        "id": "binding_2",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_2",
        "expectedOccurrences": 18,
        "sourceText": "Daily controlled_meal from Day -8 to Day 9"
      },
      {
        "id": "binding_3",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_3",
        "expectedOccurrences": 18,
        "sourceText": "Daily controlled_meal from Day 23 to Day 40"
      },
      {
        "id": "binding_4",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_4",
        "expectedOccurrences": 18,
        "sourceText": "Daily controlled_meal from Day 23 to Day 40"
      },
      {
        "id": "binding_5",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_5",
        "expectedOccurrences": 3,
        "sourceText": "Daily controlled_meal from Day -7 to Day -5"
      },
      {
        "id": "binding_6",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_6",
        "expectedOccurrences": 4,
        "sourceText": "Daily controlled_meal from Day -4 to Day -1"
      },
      {
        "id": "binding_7",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_7",
        "expectedOccurrences": 18,
        "sourceText": "Daily controlled_meal from Day -8 to Day 9"
      },
      {
        "id": "binding_8",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_8",
        "expectedOccurrences": 18,
        "sourceText": "Daily controlled_meal from Day 23 to Day 40"
      },
      {
        "id": "binding_9",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_9",
        "expectedOccurrences": 18,
        "sourceText": "Daily controlled_meal from Day -8 to Day 9"
      },
      {
        "id": "binding_10",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_10",
        "expectedOccurrences": 18,
        "sourceText": "Daily controlled_meal from Day 23 to Day 40"
      },
      {
        "id": "binding_11",
        "activityId": "controlled_meal",
        "activityName": "controlled diet",
        "repetitionId": "rep_daily_bound_11",
        "expectedOccurrences": 13,
        "sourceText": "Daily controlled_meal from Day 3 to Day 15"
      },
      {
        "id": "binding_12",
        "activityId": "balance_collection",
        "activityName": "copper balance",
        "repetitionId": "rep_daily_bound_12",
        "expectedOccurrences": 101,
        "sourceText": "Daily balance_collection from Day 101 to Day 201"
      },
      {
        "id": "binding_13",
        "activityId": "balance_collection",
        "activityName": "copper balance",
        "repetitionId": "rep_daily_bound_13",
        "expectedOccurrences": 4,
        "sourceText": "Daily balance_collection from Day -4 to Day -1"
      },
      {
        "id": "binding_14",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_14",
        "expectedOccurrences": 3,
        "sourceText": "Daily balance_collection from Day -7 to Day -5"
      },
      {
        "id": "binding_15",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_15",
        "expectedOccurrences": 4,
        "sourceText": "Daily balance_collection from Day -4 to Day -1"
      },
      {
        "id": "binding_16",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_16",
        "expectedOccurrences": 4,
        "sourceText": "Daily balance_collection from Day -4 to Day -1"
      },
      {
        "id": "binding_17",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_17",
        "expectedOccurrences": 8,
        "sourceText": "Daily balance_collection from Day 1 to Day 8"
      },
      {
        "id": "binding_18",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_18",
        "expectedOccurrences": 15,
        "sourceText": "Daily balance_collection from Day 25 to Day 39"
      },
      {
        "id": "binding_19",
        "activityId": "balance_collection",
        "activityName": "copper balance",
        "repetitionId": "rep_daily_bound_19",
        "expectedOccurrences": 101,
        "sourceText": "Daily balance_collection from Day 101 to Day 201"
      },
      {
        "id": "binding_20",
        "activityId": "balance_collection",
        "activityName": "copper balance",
        "repetitionId": "rep_daily_bound_20",
        "expectedOccurrences": 101,
        "sourceText": "Daily balance_collection from Day 101 to Day 201"
      },
      {
        "id": "binding_21",
        "activityId": "balance_collection",
        "activityName": "copper balance",
        "repetitionId": "rep_daily_bound_21",
        "expectedOccurrences": 4,
        "sourceText": "Daily balance_collection from Day -4 to Day -1"
      },
      {
        "id": "binding_22",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_22",
        "expectedOccurrences": 3,
        "sourceText": "Daily balance_collection from Day -7 to Day -5"
      },
      {
        "id": "binding_23",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_23",
        "expectedOccurrences": 4,
        "sourceText": "Daily balance_collection from Day -4 to Day -1"
      },
      {
        "id": "binding_24",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_24",
        "expectedOccurrences": 18,
        "sourceText": "Daily balance_collection from Day -8 to Day 9"
      },
      {
        "id": "binding_25",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_25",
        "expectedOccurrences": 18,
        "sourceText": "Daily balance_collection from Day 23 to Day 40"
      },
      {
        "id": "binding_26",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_26",
        "expectedOccurrences": 4,
        "sourceText": "Daily balance_collection from Day -4 to Day -1"
      },
      {
        "id": "binding_27",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_27",
        "expectedOccurrences": 8,
        "sourceText": "Daily balance_collection from Day 1 to Day 8"
      },
      {
        "id": "binding_28",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_28",
        "expectedOccurrences": 15,
        "sourceText": "Daily balance_collection from Day 25 to Day 39"
      },
      {
        "id": "binding_29",
        "activityId": "balance_collection",
        "activityName": "copper balance",
        "repetitionId": "rep_daily_bound_29",
        "expectedOccurrences": 13,
        "sourceText": "Daily balance_collection from Day 3 to Day 15"
      },
      {
        "id": "binding_30",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_30",
        "expectedOccurrences": 13,
        "sourceText": "Daily balance_collection from Day 3 to Day 15"
      },
      {
        "id": "binding_31",
        "activityId": "balance_collection",
        "activityName": "molybdenum balance",
        "repetitionId": "rep_daily_bound_31",
        "expectedOccurrences": 201,
        "sourceText": "Daily balance_collection from Day 101 to Day 301"
      },
      {
        "id": "binding_32",
        "activityId": "balance_collection",
        "activityName": "copper \nbalance",
        "repetitionId": "rep_daily_bound_32",
        "expectedOccurrences": 3,
        "sourceText": "Daily balance_collection from Day 3 to Day 5"
      },
      {
        "id": "binding_33",
        "activityId": "balance_collection",
        "activityName": "copper balance",
        "repetitionId": "rep_daily_bound_33",
        "expectedOccurrences": 101,
        "sourceText": "Daily balance_collection from Day 101 to Day 201"
      }
    ],
    "analysisWindows": [
      {
        "id": "window_baseline_1",
        "windowType": "baseline",
        "name": "Baseline Period",
        "startDay": 4,
        "endDay": -1,
        "description": "Pre-treatment baseline from Day 4 to Day -1",
        "sourceText": "Baseline Day -4 through Day -1"
      }
    ]
  }
}